Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what
effects, good and/or bad, pembrolizumab has on you, and your cancer.